Literature DB >> 17127737

Morphological characterization of the breast in Proteus syndrome complicated by ductal carcinoma in situ.

Jabed Iqbal1, Gary He, Leslie G Biesecker, Peter Rosen, Paul H Duray, Douglas Schwartzentruber, Mansor Beg, Ellen Kahn.   

Abstract

Proteus syndrome (PS) is a severe, variable, and rare disorder with asymmetric and disproportionate overgrowth of body parts, cerebriform connective tissue nevi, epidermal nevi, dysregulated adipose tissue, and vascular malformations. It is associated with benign and occasionally malignant tumors. We report the first case of ductal carcinoma in situ (DCIS) in a 28-yr-old woman with PS who underwent a mastectomy for asymmetric overgrowth. The cut surface of the tissue showed a discrete, white, lobulated, solid mass with multiple cysts with occasional small polypoid nodules. Microscopically, the tissue was characterized by neoplastic and non-neoplastic changes. The former consisted of multiple intraductal papillomas and low-grade intraductal papillary, solid, and cribriform carcinoma. The non-neoplastic changes were characterized by cysts of various sizes, lined by cuboidal or apocrine cells, focally with epithelial papillary proliferation; the lumens contained eosinophilic, mucicarmine-positive, and PAS-positive material. Variable ductal proliferation and periductal, peri- and intra-lobular fibrosis with loose fibrous connective tissue was present. The carcinoma was positive for ER, PR, CK7, and MIB-1 (40%), and negative for p53 and CK20 staining. We conclude that DCIS may be one of the tumors associated with PS and that the proliferative phenotype serves as an initiator for carcinogenesis. This case highlights the difficulty of recognizing small foci of carcinoma in an asymmetrical overgrowth of the breast in a young woman with PS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17127737

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  6 in total

1.  Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome.

Authors:  Kim M Keppler-Noreuil; Julie C Sapp; Marjorie J Lindhurst; Thomas N Darling; Jasmine Burton-Akright; Mohammadhadi Bagheri; Eva Dombi; Ashlyn Gruber; Paul F Jarosinski; Staci Martin; Neera Nathan; Scott M Paul; Ronald E Savage; Pamela L Wolters; Brian Schwartz; Brigitte C Widemann; Leslie G Biesecker
Journal:  Am J Hum Genet       Date:  2019-02-22       Impact factor: 11.025

2.  A mouse model of Proteus syndrome.

Authors:  Marjorie J Lindhurst; Lauren R Brinster; Hannah C Kondolf; Jasmine J Shwetar; Miranda R Yourick; Henoke Shiferaw; Kim M Keppler-Noreuil; Gene Elliot; Cecilia Rivas; Lisa Garrett; Julio Gomez-Rodriguez; Neil J Sebire; Stephen M Hewitt; Pamela L Schwartzberg; Leslie G Biesecker
Journal:  Hum Mol Genet       Date:  2019-09-01       Impact factor: 6.150

3.  Late-onset Proteus syndrome with cerebriform connective tissue nevus and subsequent development of intraductal papilloma.

Authors:  Emily W Modlin; Anne M Slavotinek; Thomas N Darling; Stanley Lipkowitz; Frederic G Barr; Pamela N Munster; Leslie G Biesecker; Christopher A Ours
Journal:  Am J Med Genet A       Date:  2022-04-20       Impact factor: 2.578

4.  Lack of mutation-histopathology correlation in a patient with Proteus syndrome.

Authors:  Meggie E Doucet; Hadley M Bloomhardt; Krzysztof Moroz; Marjorie J Lindhurst; Leslie G Biesecker
Journal:  Am J Med Genet A       Date:  2016-04-26       Impact factor: 2.802

5.  Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome.

Authors:  Marjorie J Lindhurst; Miranda R Yourick; Yi Yu; Ronald E Savage; Dora Ferrari; Leslie G Biesecker
Journal:  Sci Rep       Date:  2015-12-11       Impact factor: 4.379

6.  Quantifying survival in patients with Proteus syndrome.

Authors:  Julie C Sapp; Lian Hu; Jean Zhao; Ashlyn Gruber; Brian Schwartz; Dora Ferrari; Leslie G Biesecker Md
Journal:  Genet Med       Date:  2017-06-29       Impact factor: 8.822

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.